Found: 5
Select item for more details and to access through your institution.
Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1399171
- By:
- Publication type:
- Article
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta‐analysis.
- Published in:
- Pigment Cell & Melanoma Research, 2024, v. 37, n. 3, p. 352, doi. 10.1111/pcmr.13156
- By:
- Publication type:
- Article
Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 12, p. 13217, doi. 10.1002/cam4.6013
- By:
- Publication type:
- Article
Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 5, p. 773, doi. 10.1002/ijc.33844
- By:
- Publication type:
- Article
Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer.
- Published in:
- Acta Oncologica, 2010, v. 49, n. 6, p. 816, doi. 10.3109/02841861003691937
- By:
- Publication type:
- Article